Top Markets
#1 Glidr Glidr +45.67%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.65%
#3 Movement Movement +9.79%
#4 Victoria VR Victoria VR +7.64%
#5 DMT-NAT DMT-NAT +7.02%
#6 Pons Pons +6.47%
#7 MarsCoin MarsCoin +5.30%
#8 Cryptopia Cryptopia +5.23%
#9 Lisk Lisk +5.01%
#10 Jito Jito +4.63%
Coin of the day
Glidr Glidr
Settings
Language
ENGLISH
Currency
USD
Theme
Nanomix Corporation Nanomix Corporation

Nanomix Corporation

NNMX
Rank in Stocks #41810
Boston Therapeutics, Inc. focuses on the discovery, production, and... Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes. They also have IPOXYN, an injectable medication designed to prevent tissue necrosis and address conditions caused by low oxygen, such as diabetic foot ulcers and other related vascular or neurological complications. Additionally, Boston Therapeutics is progressing with BTI-410, a peptide injectable compound also in Phase II clinical development, intended to stimulate beta cell maturation in the pancreas. This could potentially serve as a new insulin-producing cell agent for individuals with type 2 diabetes and type 1 patients on immunosuppression therapy following a kidney transplant. Complementing its pharmaceutical endeavors, the company offers SUGARDOWN, a non-systemic, polysaccharide-based dietary supplement designed to support healthy blood glucose management, and OXYFEX, a veterinary application that acts as an oxygen delivery agent, similar to a red blood cell replacement, for treating ischemia, trauma, and blood loss during surgical procedures. The firm further extends its offerings to include Automatic Retinal Image Analysis (ARIA), a diagnostic tool used for screening cardiovascular risks, including stroke. Boston Therapeutics, Inc. maintains its headquarters in Lawrence, Massachusetts.
Share Price
$0.0002
Last synced: 2025-04-08
Market Cap
$9.80K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Nanomix Corporation (NNMX)

Category

Healthcare
Operating Margin for Nanomix Corporation (NNMX)
Operating Margin as of 2026 TTM: 0.00%
According to Nanomix Corporation latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Nanomix Corporation from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
17.03% -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
22.03% -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
17.86% -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
21.46% -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
28.09% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.